LABT CEO Kelvin Cooper files initial ownership report
Lakewood-Amedex Biotherapeutics Inc. director and CEO Kelvin Cooper has filed an initial Form 3 detailing his holdings in LABT.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Lakewood-Amedex Biotherapeutics Inc. director and CEO Kelvin Cooper has filed an initial Form 3 detailing his holdings in LABT. He directly holds 300,594 shares of common stock. He also holds several stock options to buy common shares at exercise prices between $2.13 and $2.78 per share, with expiration dates ranging from 2031 to 2035.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Cooper Kelvin
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Option (right to buy) | -- | -- | -- |
| Holding | Option (right to buy) | -- | -- | -- |
| Holding | Option (right to buy) | -- | -- | -- |
| Holding | Option (right to buy) | -- | -- | -- |
| Holding | Option (right to buy) | -- | -- | -- |
| Holding | Common Stock; $0.0001 par value | -- | -- | -- |
Holdings:
Option (right to buy) — 349,496 contracts (Direct);
Common Stock; $0.0001 par value — 300,594 shares (Direct)
Key Figures
Direct common shares: 300,594 shares
Option underlying shares (202,703): 202,703 shares
Option exercise price: $2.31/share
+3 more
6 metrics
Direct common shares
300,594 shares
Directly owned common stock reported on Form 3
Option underlying shares (202,703)
202,703 shares
Underlying common shares for option at $2.31 exercise price, expiring 2035-07-01
Option exercise price
$2.31/share
Exercise price for 202,703-share option grant
Option underlying shares (72,467)
72,467 shares
Underlying common shares for option at $2.13, expiring 2034-03-28
Option underlying shares (50,676)
50,676 shares
Underlying common shares for option at $2.13, expiring 2033-03-01
Option exercise price
$2.78/share
Exercise price for options over 13,514 and 10,136 underlying shares
Key Terms
Form 3, Option (right to buy, underlying security, exercise price, +1 more
5 terms
Form 3 regulatory
"Kelvin Cooper has filed an initial Form 3 detailing his holdings"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Option (right to buy financial
"The filing lists several entries titled Option (right to buy)"
underlying security financial
"Each option lists an underlying security title of Common Stock"
exercise price financial
"Options show an exercise price such as 2.31, 2.13, or 2.78"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"Each option block includes an expiration date between 2031 and 2035"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Kelvin Cooper report owning in LABT on this Form 3?
Kelvin Cooper reports direct ownership of 300,594 shares of Lakewood-Amedex Biotherapeutics common stock. In addition, he holds multiple stock options that can be exercised into common shares at preset prices and future dates, reflecting his equity-based stake as CEO and director.
What stock options does LABT CEO Kelvin Cooper hold according to this filing?
The filing lists several options to buy LABT common stock, including 202,703 underlying shares at an exercise price of $2.31 per share and additional grants at $2.13 and $2.78, with expiration dates between 2031 and 2035, all held directly.
Does this LABT Form 3 show any recent buying or selling by Kelvin Cooper?
No buy or sell transactions are shown; the Form 3 only reports existing holdings. All entries are coded as holdings with unknown transaction codes, indicating this filing serves as an initial snapshot of Cooper’s current share and option positions in Lakewood-Amedex Biotherapeutics.
What is the significance of Kelvin Cooper’s Form 3 for LABT investors?
This Form 3 shows the CEO’s baseline equity position in LABT at the time he became a reporting insider. It highlights substantial direct stock ownership plus long-term options, but does not indicate any new purchases or sales, only current beneficial ownership levels.
AI-generated analysis. How Rhea-AI works. Not financial advice.
